LLY News and Press, Eli Lilly and Company From 12/12/23

2023-12-12 07:30:00 ET Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have been the two best-performing large-cap pharma stocks over the past 10 years. The core reason is their strong competitive positions in type 2 diabetes and obesity care. Lilly's leading metaboli...

2023-12-12 07:21:29 ET Eli Lilly ( NYSE: LLY ) announced on Monday updated clinical data from a global trial of its anticancer medication, pirtobrutinib. Earlier this year, pirtobrutinib was approved under the FDA's accelerated approval pathway as Jaypirca (pirtobrutinib) to...

Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting PR Newswire INDIANAPOLIS , Dec. 11, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announc...

2023-12-11 14:27:17 ET Summary Verve Therapeutics, Inc. released positive interim data from its phase 1b heart-1 study using VERVE-101 for treating HeFH patients; LDL-C reduced by as much as 55% after a single dose. IND clearance for VERVE-101 in the U.S. opens up the inclusion of...

2023-12-11 12:54:47 ET Eli Lilly & Co (NYSE: LLY) is down nearly 4.0% today after a study indicated that weight-loss from Zepbound tends to reverse once the treatment is stopped. Patients regain weight if they stop taking Zepbound Zepbound helped patients lose close to 21% o...

2023-12-11 11:52:10 ET More on Eli Lilly Bubble Warning: Unrealistic Growth Priced In And Multiple Risk Factors For Eli Lilly Eli Lilly and Company (LLY) Presents at 6th Evercore ISI HealthCONx Conference (Transcript) Eli Lilly: Perfectly Priced Healthcare Giant ...

Lilly's Zepbound™ (tirzepatide) achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over 88 weeks PR Newswire People who were randomized to placebo following the lead-in period experi...

2023-12-10 10:41:03 ET Summary Today, we take a deeper look at United Therapeutics Corporation, whose shares are cheap but the company does have litigation concerns. The company's treprostinil products are also facing challenges from generics and clinical aspirants, and its growth...

2023-12-10 08:22:39 ET Summary A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. Introduction The D...

2023-12-10 06:56:00 ET What are some unstoppable stocks to buy right now? Three Fool.com contributors think they've found three stocks that qualify -- and they're all in the healthcare sector. Here's why they picked Axsome Therapeutics (NASDAQ: AXSM) , Eli Lilly (NYSE: LLY) ...